When ATH: N04BA02
An inhibitor of the peripheral dopa decarboxylase. In combination with levodopa, it helps to reduce the formation of dopamine in peripheral tissues and increase the amount of levodopa, entering the CNS. Do not cross the BBB.
In patients with Parkinson's after ingestion benserazide it is rapidly absorbed from the gastrointestinal tract, степень абсорбции – 58%. It is metabolized primarily in the gut, action against levodopa (in the case of a combination of levodopa benserazide) It is also carried out mainly in the intestine; in other regions of the body is metabolized to form trigidroksibenzilgidrazina. Benserazide is rapidly excreted in the urine in the form of metabolites, mainly during the first 6 hours, 85% is displayed during 12 no. Benserazide does not penetrate the blood-brain barrier in rats.
In combination with levodopa: Parkinson's disease, Parkinson's syndrome (except parkinsonism, drug-induced, in particular neuroleptics).
Individual. The daily dose of benserazide (in combination with levodopa in the ratio 1:4) It varies between 37.5 mg 250 mg.
CNS: редко – самопроизвольные движения, sleep disorders, ažitaciâ, dizziness, depression.
Cardio-vascular system: rarely - orthostatic hypotension, Arrhythmia.
From the digestive system: rarely - nausea, vomiting, anorexia, epigastric pain, dysphagia, ulcerogenic action (in predisposed patients).
From the hematopoietic system: a rare - thrombocytopenia.
The above-mentioned side effects occur when using benserazide in combination with levodopa.
Expressions of the liver, kidney, cardiovascular and / or endocrine, severe psychosis, zakrыtougolynaya glaucoma, melanoma, pregnancy, lactation, childhood, Hypersensitivity to benserazide.
Is contraindicated in pregnancy and lactation (breast-feeding).
It is used in combination with levodopa, thus reducing its dose and severity of side effects, especially nausea, vomiting, Arrhythmia. There may be a tendency to early onset of dyskinesia and mental disorders, associated with levodopa therapy.
Benserazide in combination with levodopa should not be used during treatment with MAO inhibitors (except MAO-B inhibitor).
Effects on ability to drive vehicles and management mechanisms
During the period of benserazide in combination with levodopa should avoid activities, which requires high concentration of attention and fast psychomotor reactions.
When used in combination with levodopa, along with a decrease in a number of side effects in the nervous system and the cardiovascular system, there may be a tendency to early development of dyskinesias and mental disorders, due to the action of levodopa.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More